HODGKIN & NON-HODGKIN LYMPHOMA
Late Stage Hodgkin and Non-Hodgkin Lymphoma Treatment
Personalized Lymphoma Treatment Options Designed to Precision-Target Your Cancer
Lymphoma is a complicated cancer that begins in infection-fighting cells of the immune system, called lymphocytes. There are multiple forms of this disease, like Hodgkin and Non-Hodgkin Lymphoma, as well as many subtypes, making it a very difficult cancer to diagnose and treat . For nearly two decades, patients have chosen Integrative Cancer Centers of America's personalized approach to cancer treatment as they battle lymphatic carcinomas. Our approach goes beyond conventional standard chemotherapy that is simply based on location, tissue types, cancer classifications, and staging. ICCA is a center of excellence for personalized oncology and offers the latest technology and precision-targeted cancer treatments from around the world to our patients, utilizing genetic data and in-depth testing to drive our personalized care. Every lymphatic cancer treatment protocol we provide is specifically tailored to attack the cancer causative factors such as infections, chemical toxins, and other carcinogens. Our treatment methods work to include getting the correct genetic markers and individual cancer targets for each patient's unique form of lymphoma. Based on these factors a unique "N of 1" treatment plan is put together for each patient. The method and strategy that ICCA uses to accomplish this high level of care makes us one of the top integrative centers in the world and lends to our success in helping our patients outperform.
Traditional Chemotherapy Regimens May Not Be Enough for Late-Stage and Complex Lymphomas
Standard of care relies heavily on categorization for treatment based on NCCN (National Comprehensive Cancer Network) guidelines. In our clinical experience these recommendations can work for early stage and less complicated forms of lymphoma cancer, but this is a "one-size-fits-all" mentality to cancer treatment focused primarily on type and stage. While this may prove useful for early stage cancer, in later stage cancer a stronger treatment plan needs to be put together based on actionable targets and reduction of cancer causative factors. At Integrative Cancer Centers of America, we realize that every form of cancer is unique to the individual, therefore treatment must also be completely unique and customized to your genetic findings to optimize your chances for success. Treatment must address genomic targets, immunological targets, and epigenetic targets so that the most comprehensive care is made available to you, the patient. This is the very same treatment that we would provide to our own family members; it is this type of education that empowers patients to seek alternatives to standard care.
It starts with building what we call a "true medical blueprint." The blueprint includes extensive next-generation, proprietary testing that not only considers genetic factors like tumor targets, mutations, miRNA, epigenetics, and multi-drug-resistance; but also looks at the possible underlying causes of your lymphoma. These causes may include undiagnosed infections, environmental influences, chemical toxins, and random genetic mutations, all of which can lead to a weakened immune system which may contribute to the spread of disease.
According to the American Cancer Society, in 2019 alone there will be an estimated 8,110 new cases of Hodgkin Lymphoma. Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, with an estimated 74,200 people (41,090 male and 33,110 female) diagnosed in 2019  . Though both these cancers have a five-year survival rate higher than 70% (about 71% for Non-Hodgkin and 86% for Hodgkin lymphoma  ), for those with more complex and refractory cancers that are not responding to care, they may need additional targeting and precision offered by the ICCA medical team. Most patients who come to ICCA have exhausted their options on the conventional side of medicine and are looking for a more personalized and targeted approach to their cancer treatment. But it is our hope that in the future that all patients have access to this type of personalized care. Our clinical experience has shown that personalization allows for far better targeting and improves treatment options for patients.
Going Beyond Traditional Diagnostics and Testing for Lymphoma Patients
ICCA's in-depth genomic testing methods go beyond the traditional diagnostic methods of biopsies and imaging. At ICCA we are utilizing next level genetic targets by utilizing circulating tumor cells and MiRNA mutational data, in conjunction with specialty world-class labs and tests, to create an in-depth blueprint of your specific cancer based around your specific cancer. This makes you at ICCA "N of 1." This simply means that your treatment plan is built only for you and each individual patient has their own treatment plan customized to them, it is not a one-size-fits-all model. We believe the future of cancer treatment will be going in this direction someday but in the meantime ICCA continues to go above-and-beyond for our patients. Your true medical blueprint is the empirical foundation from which we can start to build your comprehensive cancer treatment protocol, but it is only one half of the equation. The important part is utilizing that data to provide customized, patient-specific treatment options targeted to your genetic mutations. ICCA builds your protocol by combining targeted medications for your unique disease presentation, attacking multiple genetic targets, immunotherapy targets, and creating a synergistic therapeutic effect. In general terms, it is putting all the therapies together creating a greater momentum for you, the patient, while potentially minimizing side-effects.
Conventional chemotherapy, a common standard of care treatment for both Hodgkin and non-Hodgkin lymphomas, often uses standard chemotherapy regimens that may have devastating effects on the surrounding tissues and other organs of the body if the wrong drugs are selected and administered at "maximum therapeutic dose." The goal behind giving maximum therapeutic doses of chemotherapy is to hopefully give enough chemotherapy drugs to potentially kill the tumor before those same drugs becoming overwhelming and destroy the body's immune system. Instead of delivering maximum therapeutic doses, we at ICCA believe drug selection should be the number one focus, and once the selection is correct, metronomic or micro-dosing may be a far more precise method for drug delivery. Micro-dosing allows for utilization of multiple drug targets all at one time with the potential minimization of side-effects. However, immunotherapy is absolutely critical for the treatment of lymphoma. Immunotherapy is a unique type of treatment that uses the body's own immune system to fight cancer. In our clinical experience, we find that the proper targeted immunotherapy options provide a better quality of life and long-term outcomes in our patient base. We work to establish a strong immune system by addressing additional factors like toxins, infections, and other carcinogens which are essential to remove in the treatment of both Hodgkin and non-Hodgkin's lymphoma. Integrative Cancer Centers of America has created a proprietary form of precision chemotherapy that can target your specific cancer while potentially reducing the negative side-effects of chemotherapy; most importantly this method of administration is completely customizable to your genetic findings.
Genetically Targeted Fractionated Chemotherapy for Lymphoma
Genetically Targeted Fractionated Chemotherapy, or GTFC, is an exclusive treatment program developed by Integrative Cancer Centers of America. GTFC offers a synergetic combination of genetically targeted, micro-dosed chemotherapies with cancer adjunctive agents to provide a treatment that can hit more biomarker targets than standardized cancer treatment, while providing the possibility of reduced negative secondary responses . Many of our patients experience little to no side-effects while receiving GTFC and are even able to hike and go to the gym during treatment. This is a result of increased treatment accuracy, fractionated doses of chemotherapy, and adjunctive agents designed to aid in the recovery of the body and immune system while attacking the cancer.
GTFC works by targeting more genetic biomarkers than normal chemotherapy. We use metagenomic analysis to find multiple chemotherapies and cancer adjunctive agents that your specific cancer is susceptible to. Then we utilize an exclusive complex algorithm and leading-edge bioinformatic assays to build a treatment protocol that utilizes multiple points of action to create a synergistic approach.
Chemotherapy agents are designed to work on differing mechanisms of action to attack cancer. Some slow the mutation of cancer, some slow the signaling of cancer cells, some produce an immune response, and finally, others work to kill tumor cells. Most treatment options will often only utilize one or two of these mechanisms of action at a time. Because GTFC utilizes a fractionated dosage, we can use multiple chemotherapies with differing mechanisms of action as part of a single treatment protocol. We blitz cancer with an array of precision-targeted cancer agents, supportive integrative approaches, and patient specific methods to potentially improve patient outcomes.
GTFC is ICCA's method for providing a multifaceted, genetically targeted chemotherapy. It represents a major tactic we use for treating cancer itself, but it does not represent the extent of our abilities at Integrative Cancer Centers of America. In nearly twenty years of treating the most difficult cancer cases, we have the clinical experience to know that treating cancer alone is not enough to achieve lasting results. So, in addition to GTFC, ICCA utilizes a multitude of methods to address the patient's immune system and to treat underlying factors that may be contributing to or even causing your cancer. There are many infections, toxins, and autoimmune diseases that have been correlated with lymphoma and must be addressed. Non-Hodgkin Lymphoma has been correlated with infections like the human T-cell lymphotropic virus and the human herpesvirus 8 . Also, Non-Hodgkin Lymphoma has been connected to toxins like benzene and certain herbicides . Both Non-Hodgkin and Hodgkin lymphoma have been correlated with the Epstein-Barr virus. These factors are virtually ignored by the conventional system and are not always addressed properly in the integrative model. From our clinical experience, at the root of most lymphomas are undiagnosed causative agents such as chronic infections and chemical toxins that require in-depth testing and treatment.
Hodgkin's and Non-Hodgkin's Lymphoma Immunotherapy Options
A weakened immune system may be considered one of the biggest risk factors for developing Lymphoma  , It is important to note that when utilizing standard chemotherapy if it is not targeting the cancer correctly it may also be weakening the immune system. Integrative Cancer Centers of America's approach is world-class and offers genetically targeted immunotherapy and immunotherapy adjunctive agents as an integral part of lymphatic cancer treatment modalities. We use a multitude of detoxification methods to remove heavy metals and toxins that can wreak havoc on a patient's health and promote the spread of disease. All of this is made possible because we operate our own in-house custom pharmacy to build patient-specific IVs and medications for all our treatments based on patient specific genetic targets.
The CIPI ™ Advantage
Aggressive cancers like late-stage Hodgkin or Non-Hodgkin Lymphoma that have metastasized to difficult-to-reach organs often need highly specialized treatment modalities to achieve optimal success. One of ICCA Medical Center's revolutionary Stage 4 Lymphoma treatment options is CIPI ™, or Chemo Immunotherapy Percutaneous Injections. Combining precision targeted, micro-dosage chemotherapy with advanced genomic-based adjuvant immunotherapy, the CIPI ™ procedure is ICCA's proprietary form of chemoembolization. CIPI ™ directly targets the tumor cite for precision delivery of customized chemotherapies, specifically tailored for each individual patient and their unique Lymphoma expression. In addition, advanced patient driven immunotherapy protocols offer personalized adjunctive support that works to revitalize and bolster the immune system. Potentially increasing tumor kill and possibly reducing many of the negative side-effects of associated with traditional chemotherapy administration. Leading edge approaches like CIPI ™ are one of the many reasons that more and more patients are turning to ICCA for new and exciting alternative options for personalized late-stage lymphatic cancer care. Consult with ICCA physicians to see if CIPI ™ is right for you.
ICCA has spent decades researching and developing clinically proven therapies and methods to customize and tailor our treatment options. Based on our patients' statements and years of experience, ICCA operates at a higher personalized integrative level. We offer one-of-a-kind precision integrative treatment options with unmatched care and compassion. Our goal is to provide the highest quality compassionate care to help our patients make meaningful and life-changing progress in the fight against their disease. If you or one of your loved have questions about ICCA's Hodgkin or Non-Hodgkin Lymphoma treatment, please contact our Patient Care Coordinator team at (888) 526-6398 and let us help you on your path to treatment. And may God bless you on your journey to healing!
 Society, A.C. What Is Non-Hodgkin Lymphoma? 2019 [cited 2019 11/6]; Available from: https://www.cancer.org/
 Society, A.C. Hodgkin Lymphoma Risk Factors. 2019 [cited 2019 11/6]; Available from: https://www.cancer.org/
 Society, A.C. Non-Hodgkin Lymphoma Risk Factors. 2019 [cited 2019 11/6]; Available from: https://www.cancer.org/
 Society, A.C. Key Statistics for Hodgkin Lymphoma. 2019 [cited 2019 11/6]; Available from: https://www.cancer.org/
 Society, A.C. Key Statistics for Non-Hodgkin Lymphoma. 2019 [cited 2019 11/6]; Available from: https://www.cancer.org/
 Smith, A.J., J. Oertle, and D.J.J.o.C.T. Prato, Genetically Targeted Fractionated Chemotherapy. 2015. 6(02): p. 182.